QUOTE AND NEWS
Market Intelligence Center  Nov 12  Comment 
BioMarin Pharmaceutical (BMRN) traded between $85.77 and $87.50 before closing at $86.12 Tuesday and presents some attractive trading opportunities today. MarketIntelligenceCenter.com’s patented algorithms selected a Jan. '15 $85.00 covered call...
Benzinga  Nov 10  Comment 
Regulus Therapeutics (NASDAQ: RGLS) shares reached a new 52-week high of $25.251. Regulus Therapeutics shares have jumped 265.56% over the past 52 weeks, while the S&P 500 index has gained 14.68% in the same period. BioMarin Pharmaceutical...
Benzinga  Nov 10  Comment 
Goldman Sachs upgraded BioMarin Pharmaceutical (NASDAQ: BMRN) from Neutral to Buy. The price target for BioMarin Pharmaceutical has been raised from $78.00 to $104.00. BioMarin Pharmaceutical shares have gained 35.34% over the past 52 weeks,...
Benzinga  Nov 10  Comment 
Motley Fool  Nov 5  Comment 
BioMarin Pharmaceutical was among the best-performing biotech stocks in October. Find out why shares took off and whether or not BioMarin can head even higher.
StreetInsider.com  Nov 3  Comment 
UPGRADES Citi upgrades TD Ameritrade (NYSE: AMTD) from Neutral to Buy. Goldman Sachs moves Crown Castle (NYSE: CCI) from Neutral to Buy and adjusts its price target from $86 up to $94. Click Here for more color. Wells Fargo boosts BioMarin...
Motley Fool  Oct 24  Comment 
A solid third quarter puts BioMarin on target for more than $700 million in revenue this year, within striking distance of $1 billion in annual revenue.
newratings.com  Oct 24  Comment 
WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc (BMRN) Thursday reported third-quarter net earnings of $7.4 million or $0.05 per share compared with a loss of $53 million or $0.38 per share last year. Excluding items, adjusted loss for the...
Market Intelligence Center  Oct 17  Comment 
After closing Thursday at $70.59, BioMarin Pharmaceutical (BMRN) presents an attractive opportunity to get a 6.72% return in just 92 days, which is an annualized return of 26.68% (for comparison purposes only). To enter this trade, sell one Jan....




 

BioMarin Pharmaceutical Inc. (BMRN), a developer of enzyme-related therapies (ERT), co-markets Aldurazyme with Genzyme Corporation (GENZ) for the treatment of MPS-I (mucopolysaccharidosis). MPS-I is a rare genetic enzyme deficiency disorder, afflicting roughly 3,000 people worldwide, caused by the lack of a specific enzyme involved in lysosomal storage. More common names for mucopolysaccharidosis are Hurler's Syndrome, Hurler-Scheie, and Scheie's Disease. The company's other developed product, Naglazyme, for MPS-VI, recently entered the market. MPS-VI is also a rare genetic enzyme deficiency disorder, with an estimated 1,100 people suffering from it worldwide. The company's third lead drug, Kuvan, received FDA approval for the treatment of PKU in December 2007. With the recent launch of Kuvan, the company now has three products on the market. The company also receives royalties and license revenue on sales of the Orapred franchise from Alliant Pharmaceuticals. In 2004, the company acquired Orapred, a grape-flavored oral corticosteroid liquid for the treatment of severe asthma in children and subsequently licensed the franchise to Alliant Pharmaceuticals in March 2006. BioMarin, headquartered in Novato, CA, employs roughly 300 people.

Business Overview

Business & Financial Metrics

In 2009, BMRN incurred a net loss of $488 thousand on revenues of $324.7 million. This represents a real turnaround from 2008, when the company earned $30.8 million on $296.5 million in revenues.[1]

Geographical Distribution[2]

BioMarin generates the majority of its revenues from sales in Europe.

IMAGE:BMRN-Geography2009.jpg[2]

Competition

BioMarin competes with companies like:

References

  1. BMRN 2009 10-K pg. 36  
  2. 2.0 2.1 BMRN 2009 10-K pg. 16  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki